Document is current
Any future updates will be listed below
-
Authors
Boons, Eline
Nogueira, Tatiane C.
Dierckx, Tim https://orcid.org/0000-0002-1969-7974
Menezes, Soraya Maria
Jacquemyn, Maarten https://orcid.org/0000-0003-2626-4189
Tamir, Sharon
Landesman, Yosef
Farré, Lourdes
Bittencourt, Achiléa
Kataoka, Keisuke https://orcid.org/0000-0002-8263-9902
Ogawa, Seishi
Snoeck, Robert
Andrei, Graciela
Van Weyenbergh, Johan https://orcid.org/0000-0003-3234-8426
Daelemans, Dirk https://orcid.org/0000-0001-7092-1153
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (PhD grant, PhD grant, G0D6817N)
Japan Agency for Medical Research and Development (JP119cm0106501h0004)
Kyoto University (KAKENHI 15H05909)
KU Leuven (Vaast Leysen Leerstoel voor Infectieziekten in Ontwikkelingslanden)
- License Information
-
More Information
Article History
Received: 1 September 2020
Revised: 10 December 2020
Accepted: 17 December 2020
First Online: 1 February 2021
Conflict of interest
: S.T. and Y.L. are employees of the manufacturer of selinexor (Karyopharm Therapeutics Inc). D.D., J.V.W., R.S., G.A., and T.D. are employees of KU Leuven. KU Leuven has a license agreement on XPO1 inhibitors (selinexor). Karyopharm and KU Leuven had no direct involvement in the interpretation of the results of this study. All other authors declare that they have no competing interests.
